Globalization, Evolution and Emergence of Direct-to-Consumer Advertising: Are Emerging Markets the Next Pharmaceutical Marketing Frontier?
Requires Subscription or Fee PDF


Global health
direct-to-consumer advertising
emerging markets
pharmaceutical marketing
international law
health policy


Pharmaceutical marketing has rapidly evolved over the past century and has now entered the digital revolution.  This is exemplified by the rise of direct-to-consumer-advertising (“DTCAâ€), which has traditionally been only allowed in the United States and New Zealand in developed countries, but is now expanding in reach to other jurisdictions.  Enabling the “globalization†of pharmaceutical DTCA is Internet-related technologies that are not limited to geographical borders and are highly unregulated.  This DTCA digital “spillover†into markets that prohibit it can have adverse impact on health outcomes and health-related spending.  Emerging markets may represent the next logically step for digital DTCA proliferation, given their untapped market potential and explosive growth.  Further research and global health policy reform is necessary to address this “emerging†global health issue.
Requires Subscription or Fee PDF



Applbaum K. (2006) Pharmaceutical Marketing and the Invention of the Medical Consumer. PLoS Medicine 3(4): e189.

Donohue JM, Cevasco M, Rosenthal MB. (2007) A decade of direct-to-consumer advertising of prescription drugs. New England Journal of Medicine 357(7): 673–81.

U.S. Department of Human and Health Services. (2012) Health Care Fraud Prevention and Enforcement Efforts Result in Record-Breaking Recoveries Totaling Nearly $4.1 Billion. News Release, 14 February,, accessed 18 May 2012.

Liang BA, Mackey T. (2011) Reforming direct-to-consumer advertising. Nature Biotechnology 29(5):397–400.

Palumbo FB, Mullins CD. (2005) The development of direct-to-consumer prescription drug advertising regulation. Food and Drug Law Journal 57(3):423–43.

Kaiser. (2008) Kaiser Public Opinion Spotlight: Public and Physician Views of Direct-to-Consumer Prescription Drug Advertising. Kaiser Public Opinion Spotlight, April,, accessed 18 May 2012.

Paek HJ, Lee H, Praet CLC, Chan K, Chien PM, Huh J, et al. (2011) Pharmaceutical Advertising in Korea, Japan, Hong Kong, Australia, and the US: Current Conditions and Future Directions. Health Communication Research 3(1):1–63.

Kelly P. (2004) Perspective: DTC Advertising's Benefits Far Outweigh Its Imperfections. Health Affairs, 28 April,, accessed 17 May 2012.

IMS. (2009) Total US Promotional Spend by Type, 2009., 2009,, accessed 20 May 2012.

U S Government Accountability Office. (2006) GAO-07-54 Prescription Drugs: Improvements Needed in FDA's Oversight of Direct-to-Consumer Advertising. U.S. GAO, November,, accessed 20 May 2012.

Wolfe SM. (2002) Direct-to-consumer advertising—Education or emotion promotion? New England Journal of Medicine 346(7):524–6.

Eysenbach G. (2008) Medicine 2.0: social networking, collaboration, participation, apomediation, and openness. Journal of Medical Internet Research 10(3):e22.

Liang BA, Mackey TK. (2011) Prevalence and Global Health Implications of Social Media in Direct-to-Consumer Drug Advertising. Journal of Medical Internet Research 13(3):e64.

“Cyberchondriacs†on the Rise? (2010) Harris Polls. 4 August,, accessed 21 May 2012.

Liang BA, Mackey T. (2011) Direct-to-consumer advertising with interactive internet media: global regulation and public health issues. Journal of American Medical Association 305(8):824–5.

Frosch DL, Grande D, Tarn DM, Kravitz RL. (2009) A Decade of Controversy: Balancing Policy With Evidence in the Regulation of Prescription Drug Advertising. American Journal of Public Health 100(1):24–32.

Vastag B. (2007) US aims to tighten rules on direct-to-consumer drug ads. Nature Biotechnology 25(3):267.

Kolata G. (2010) When Drugs Cause Problems They Are Supposed to Prevent., 16 October,, accessed 21 May 2012.

Direct-to-consumer advertising under fire. (2009) Bulletin of the World Health Organization 87(8):576–7.

Mackey T, Liang B. (2011) Off Label Promotion Reform: A Legislative Proposal Addressing Vulnerable Patient Drug Access and Limiting Inappropriate Pharmaceutical Marketing. University of Michigan Journal of Law Reform 45(1):1-54.

Cohen R, Stussman B. (2010) Health information technology use among men and women aged 18–64: early release of estimates from the National Health Interview Survey, January–June 2009. National Center for Health Statistics, February,, accessed 21 May 2012.

U.S. Congressional Budget Office. (2011) Potential Effects of a Ban on Direct-to-Consumer Advertising of New Prescription Drugs. Economic and Budget Issue Brief, May,, accessed 21 May 2012.

Brekke KR, Kuhn M. (2006) Direct to consumer advertising in pharmaceutical markets. Journal of Health Economics 25(1):102-130.

National Institute for Health Care Management. (2000) Prescription Drugs and Mass Media Advertising. Research Brief, September,, accessed 21 May 2012.

Shuchman M. (2007) Drug risks and free speech--can Congress ban consumer drug ads? New England Journal of Medicine 356(22):2236–9.

Law MR, Majumdar SR, Soumerai SB. (2008) Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study. BMJ 337:a1055.

Mintzes B, Morgan S, Wright JM. (2009) Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale. PLoS ONE 4(5):e5699.

Mintzes B. (2008) Direct to consumer advertising of prescription drugs. BMJ 337:a985.

Mackenzie FJ, Jordens CFC, Ankeny RA, McPhee J, Kerridge IH. (2007) Direct-to-consumer advertising under the radar: the need for realistic drugs policy in Australia. Internal Medicine Journal 37(4):224–8.

Toop L, Richards D, Saunders B. (2003) New Zealand deserves better. Direct-to-consumer advertising (DTCA) of prescription medicines in New Zealand: for health or for profit? The New Zealand Medical Journal 116:U556.

Burton B. Drug industry to fight New Zealand's move to ban direct to consumer advertising. (2004) BMJ 328(7447):1036–0.

Velo G, Moretti U. (2008) Direct-to-consumer information in Europe: the blurred margin between promotion and information. British Journal of Clinical Pharmacology 66(5):626–8.

Hobson K. (2010) Report: Pharma Digital Spending Growing — But Slowly. Wall Street Journal Blogs, 26 August,, accessed 21 May 2012.

Kuehn BM. (2010) FDA weighs limits for online ads. Journal of American Medical Association 303(4):311–3.

Liang BA, Mackey T. (2009) Searching for safety: addressing search engine, website, and provider accountability for illicit online drug sales. American Journal of Law and Medicine 35(1):125–84.

Liang BA, Mackey TK. (2012) Online availability and safety of drugs in shortage: a descriptive study of internet vendor characteristics. Journal of Medical Internet Research 14(1):e27.

Keys M. (2012) Facebook publishes new data on users in amended S-1 filing. Reuters Blogs. 23 April,, accessed 21 May 2012.

Campbell D, Chui M. (2010) Pharmerging shake-up: New imperatives in a redefined world. imshealthcom., accessed 21 May 2012.

Pricewaterhousecoopers. (2007) Pharma 2020: The vision: Which path will you take? Pharma 2020 series,, accessed 21 May 2012.

IMS. (2010) Total Unaudited and Audited Global Pharmaceutical Market By Region.,, accessed 21 May 2012.

World Diabetes Foundation. Diabetes facts. 15 March,, accessed 21 May 2012.

Pricewaterhousecoopers. (2009) Pharma 2020: Marketing the future - Which path will you take? Pharma 2020 series,, accessed 21 May 2012.

Harris G, Singer N. (2010) U.S. Broadens Bribery Inquiry Into Drug Makers [Internet]., 13 August,, accessed 21 May 2012.

U.K. Serious Fraud Office. (2010) British executive jailed for part in Greek healthcare corruption. Press Releases 2010, 14 April,, accessed 21 May 2012.

Mackey TK, Liang BA. (2011) The global counterfeit drug trade: patient safety and public health risks. Journal of Pharmaceutical Sciences 100(11):4571–9.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.